Want to track RNAC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
Cartesian Therapeutics said on Tuesday that its experimental autoimmune disorder therapy met the main goal of a mid-stage trial.
Reuters | 2 years ago
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
The FDA bestows RMAT designation to Cartesian's (RNAC) lead pipeline candidate, Descartes-08, for treating myasthenia gravis. Shares rise.
Zacks | 2 years ago
